403 related articles for article (PubMed ID: 32700072)
1. The Time Has Come for Targeted Therapies for AML: Lights and Shadows.
Fiorentini A; Capelli D; Saraceni F; Menotti D; Poloni A; Olivieri A
Oncol Ther; 2020 Jun; 8(1):13-32. PubMed ID: 32700072
[TBL] [Abstract][Full Text] [Related]
2. New drugs creating new challenges in acute myeloid leukemia.
Tiong IS; Wei AH
Genes Chromosomes Cancer; 2019 Dec; 58(12):903-914. PubMed ID: 30861214
[TBL] [Abstract][Full Text] [Related]
3. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia.
Kantarjian H; Short NJ; DiNardo C; Stein EM; Daver N; Perl AE; Wang ES; Wei A; Tallman M
Lancet Haematol; 2021 Dec; 8(12):e922-e933. PubMed ID: 34687602
[TBL] [Abstract][Full Text] [Related]
4. What to use to treat AML: the role of emerging therapies.
Thol F
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):16-23. PubMed ID: 34889359
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax-based therapies for acute myeloid leukemia.
Guerra VA; DiNardo C; Konopleva M
Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
[TBL] [Abstract][Full Text] [Related]
6. [Incorporation of novel agents into the treatment for acute myeloid leukemia].
Yamauchi T
Rinsho Ketsueki; 2018; 59(10):1988-1996. PubMed ID: 30305501
[TBL] [Abstract][Full Text] [Related]
7. Acute myeloid leukemia transformed to a targetable disease.
Saleh K; Khalifeh-Saleh N; Kourie HR
Future Oncol; 2020 May; 16(14):961-972. PubMed ID: 32297538
[TBL] [Abstract][Full Text] [Related]
8. Incorporating newer agents in the treatment of acute myeloid leukemia.
Raj RV; Abedin SM; Atallah E
Leuk Res; 2018 Nov; 74():113-120. PubMed ID: 30401522
[TBL] [Abstract][Full Text] [Related]
9. Progress and predictions: AML in 2018.
Rowe JM
Best Pract Res Clin Haematol; 2018 Dec; 31(4):337-340. PubMed ID: 30466743
[TBL] [Abstract][Full Text] [Related]
10. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
Wei AH; Tiong IS
Blood; 2017 Dec; 130(23):2469-2474. PubMed ID: 29051180
[TBL] [Abstract][Full Text] [Related]
11. Will new agents impact survival in AML?
Rowe JM
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101094. PubMed ID: 31779986
[TBL] [Abstract][Full Text] [Related]
12. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia?
Bewersdorf JP; Stahl M; Zeidan AM
Leuk Lymphoma; 2019 Jun; 60(6):1354-1369. PubMed ID: 30652518
[TBL] [Abstract][Full Text] [Related]
13. Which new agents will be incorporated into frontline therapy in acute myeloid leukemia?
Stone RM
Best Pract Res Clin Haematol; 2017 Dec; 30(4):312-316. PubMed ID: 29156201
[TBL] [Abstract][Full Text] [Related]
14. Novel Agents for Acute Myeloid Leukemia.
Luppi M; Fabbiano F; Visani G; Martinelli G; Venditti A
Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30423907
[TBL] [Abstract][Full Text] [Related]
15. [Novel Strategies to Treat Acute Myeloid Leukemia].
Gediga MHE; Middeke JM; Ruhnke L
Dtsch Med Wochenschr; 2023 Apr; 148(8):451-458. PubMed ID: 36990117
[TBL] [Abstract][Full Text] [Related]
16. New Targeted Agents in Acute Myeloid Leukemia: New Hope on the Rise.
Bohl SR; Bullinger L; Rücker FG
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31018543
[TBL] [Abstract][Full Text] [Related]
17. Single-agent and combination biologics in acute myeloid leukemia.
Richard-Carpentier G; DiNardo CD
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):548-556. PubMed ID: 31808888
[TBL] [Abstract][Full Text] [Related]
18. Ivosidenib in acute myeloid leukemia.
Bruzzese A; Labanca C; Martino EA; Mendicino F; Lucia E; Olivito V; Neri A; Imovilli A; Morabito F; Vigna E; Gentile M
Expert Opin Pharmacother; 2023; 24(18):2093-2100. PubMed ID: 37874005
[TBL] [Abstract][Full Text] [Related]
19. How I treat acute myeloid leukemia in the era of new drugs.
DiNardo CD; Wei AH
Blood; 2020 Jan; 135(2):85-96. PubMed ID: 31765470
[TBL] [Abstract][Full Text] [Related]
20. Glasdegib for the treatment of acute myeloid leukemia.
Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Fimognari F; Neri A; Morabito F; Vigna E; Gentile M
Expert Opin Pharmacother; 2023; 24(14):1537-1543. PubMed ID: 37392098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
